Boston Scientific shares have declined by 6.3% over the past four weeks, pushing key momentum indicators into oversold territory for the first time since May 2024. The 14-day Relative Strength Index fell below 30 on January 12, suggesting that recent selling pressure may have exhausted. Historically, BSX has recorded an average 3.8% bounce over the subsequent two weeks when the RSI dips below this threshold, a pattern that technical traders view as a potential entry signal.

Wall Street analysts have grown increasingly bullish on Boston Scientific’s near-term profit prospects. Over the last month, 10 of the 14 firms covering BSX have raised their 2026 adjusted earnings per share forecasts, lifting the consensus estimate by 4.2% to $2.05. This collective upgrade follows better-than-expected performance in the cardiovascular and neuromodulation divisions, where December quarter revenue exceeded internal targets by roughly $150 million.

Despite improving fundamentals, investor anxiety resurfaced after BSX disclosed potential initial earnings dilution related to its $3.2 billion acquisition of Penumbra. In the company’s latest investor presentation, management projected the deal could reduce 2025 EPS by up to 6 cents, before accreting by 8 cents in 2026. The stock slid 8.5% over five trading days following this disclosure, underlining market sensitivity to near-term margin pressures.

With shares trading near a seven-month low and a forward price-to-earnings multiple approximately 10% below the five-year average, BSX may offer an attractive entry point for patient investors. The company forecasts mid-single-digit organic revenue growth in 2026, underpinned by new product launches in peripheral interventions and a $200 million cost-synergy program tied to the Penumbra deal. If management meets these targets, the stock could see a meaningful revaluation over the next 12 to 18 months.